课题基金 / 基金详情

Role of the atypical ERK3/ERK4-MK5 signaling pathway in cell cycle progression and tumorigenesis

Role of the atypical ERK3/ERK4-MK5 signaling pathway in cell cycle progression and tumorigenesis
非典型 ERK3/ERK4-MK5 信号通路在细胞周期进展和肿瘤发生中的作用
批准号：
171118
负责人：
Meloche Sylvain
金额：
$64.7万
依托单位：
Institute for Research in Immunology and Cancer (Montreal, QC)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2008
资助国家：
加拿大
项目状态：
已结题
起止时间：
2008-09-01 至 2013-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=171118&lang=en
关键词：
Cancer Cell Cycle Map Kinases Mouse Genetics Oncogene-Induced Senescence Signal Transduction

项目摘要

项目成果

Meloche Sylvain的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
MAP kinases are a family of enzymes that play important roles in the control of cell proliferation and survival. Accumulating evidence suggests that these enzymes may be implicated in the pathogenesis of cancer. Our laboratory has identified a novel pathw
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression
Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4
Role and therapeutic potential of ERK3/ERK4 MAP kinases in acute kidney injury
Regulation, downstream targets and functional specificity of the MAP kinases ERK1 and ERK2
海外基金